~~<i id='93AFD9AAF5'><strike id='93AFD9AAF5'><tt id='93AFD9AAF5'><pre id='93AFD9AAF5'></pre></tt></strike></i>~~

Home» leisure time» entertainment

entertainment

author：comprehensive 2025-09-06 07:20:17 Page View：7568

Michel Pairet -- health business coverage from STAT — Michel Pairet Courtesy Boehringer Ingelheim

LONDON — At an event here last week, the German pharmaceutical firm Boehringer Ingelheim outlined the projects in its pipeline.

There was obesity and liver disease, and computational biology and oncology. Then respiratory and inflammatory diseases. And don’t forget mental illness and retinal health. Oh, it was also the day the company launched another Humira biosimilar.

In other words, there was a whole lot for the company to discuss as it works to promote its breadth and build partnerships with academic researchers and other companies.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Readout Newsletter: Illumina, CRISPR, Regeneron
Next article： Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

explore

Novavax promises a turnaround & Lilly roils the obesity market

SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We

FDA approves Leqembi, a milestone in Alzheimer’s treatment

Amyloidplaquesformingbetweenneurons.AdobeTheFoodandDrugAdministrationonThursdaygrantedfullapprovalto

Hepatitis C has a cure — but many Americans still lack access to it

AdobeIn2005,NickVoyleswasdiagnosedwithhepatitisCafterbeingreleasedfromfiveyearsofincarceration.Anurs

CRISPR technology availability, affordability needs to be expanded

Fromleft,STAT'sJasonMast;JuliaVitarello,founder&CEOofMila’sMiracleFoundation;andFyodorUrnov,agen